Overview

A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants

Status:
COMPLETED
Trial end date:
2024-10-28
Target enrollment:
Participant gender:
Summary
This study is intended to evaluate the PK, safety, and tolerability of balcinrenone/dapagliflozin given as a single dose capsule to healthy Chinese participants.
Phase:
PHASE1
Details
Lead Sponsor:
AstraZeneca
Treatments:
dapagliflozin